BioCryst Pharmaceuticals Inc
Here’s whether BioCryst Pharmaceuticals Inc (BCRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 39 — healthy momentum range. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.46% over 10 days); weak 1-year return of -23.4%. Currently 25.1% off its 52-week high. Score: +0/7.
BCRX is holding above its long-term 200-day MA ($7.92) but has slipped below the 50-day MA ($9.05), pointing to short-term weakness in an otherwise intact trend. An RSI of 38.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -23.4% compares to +24.4% for SPY (trailed the market by 47.8%). The current 25.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.